Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453088 · ClinicalTrials.gov registry record · Phase 2
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
A Phase 2 study, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01453088 is a Phase 2 study that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 63 participants.
The verdict
NCT01453088, a Phase 2 study, was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.
Interventions
- DRUG Melphalan
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-06-24 |
| Est. Completion | 2022-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453088
The ClinicalTrials.gov registry entry for NCT01453088 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melphalan is the first listed.
NCT01453088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01453088 about?
NCT01453088 is a clinical study titled "Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older". In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.
What is the current status of trial NCT01453088?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2010-06-24. Estimated completion is 2022-05-01.
What interventions are being tested in trial NCT01453088?
The interventions under investigation include: Melphalan (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01453088?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.